

1 STATE OF OKLAHOMA

2 2nd Session of the 52nd Legislature (2010)

3 SENATE CONCURRENT  
4 RESOLUTION 62

By: Crain

5  
6 AS INTRODUCED

7 A Concurrent Resolution encouraging the Medicaid Drug  
8 Utilization Review Board within the Oklahoma Health  
9 Care Authority to amend certain program; and  
10 directing distribution.

11 WHEREAS, the Medicaid Drug Utilization Review Board within the  
12 Oklahoma Health Care Authority is authorized by Section 5030.5 of  
13 Title 63 of the Oklahoma Statutes to recommend and implement  
14 product-based prior authorization programs for drugs or drug classes  
15 covered under the Oklahoma Medicaid program; and

16 WHEREAS, the Oklahoma Health Care Authority Board approved a  
17 product-based prior authorization program for atypical  
18 antipsychotics at the Oklahoma Health Care Authority Board meeting  
19 on March 11, 2010; and

20 WHEREAS, the product-based prior authorization program for  
21 atypical antipsychotics approved by the Oklahoma Health Care  
22 Authority Board would classify atypical antipsychotic drugs into  
23 three tiers of authorization; and  
24

1       WHEREAS, the product-based prior authorization program for  
2 atypical antipsychotics approved by the Oklahoma Health Care  
3 Authority Board would require some persons on Medicaid to undergo a  
4 fourteen-day trial of one Tier One medication and all Tier Two  
5 medications before advancing to a Tier Three medication; and

6       WHEREAS, atypical antipsychotics are used to used to treat  
7 psychiatric conditions, including schizophrenia, acute mania,  
8 bipolar mania and psychotic agitation; and

9       WHEREAS, delaying the prescription of more effective medications  
10 to persons with a serious psychiatric condition could have a  
11 negative effect on their health.

12       NOW, THEREFORE, BE IT RESOLVED BY THE SENATE OF THE 2ND SESSION  
13 OF THE 52ND OKLAHOMA LEGISLATURE, THE HOUSE OF REPRESENTATIVES  
14 CONCURRING THEREIN:

15       THAT the Legislature encourages the Medicaid Drug Utilization  
16 Review Board within the Oklahoma Health Care Authority to amend the  
17 product-based prior authorization program for atypical antipsychotic  
18 medications to require a trial of only one drug per tier before  
19 authorizing an atypical antipsychotic in a higher tier.

20       THAT the Secretary of State shall distribute a copy of this  
21 resolution to the Oklahoma Health Care Authority Board.

22  
23       52-2-3951       JM       5/10/2010 11:32:31 AM

24